Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB).
Dr Adusumilli is Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center at the Memorial Sloan Kettering Cancer Center in New York.
Dr Adusimilli is a world-renowned thoracic surgeon with expertise in the diagnosis and treatment of cancers in the chest — lung cancer, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumours, and cancers metastatic to lung and pleura.
OVs are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.
Imugene managing director and CEO, Leslie Chong, said, “It is a great honour for Imugene to have such a distinguished physician and scientist join our team. Dr Adusumilli has devoted his career and his scientific discoveries for the benefit of cancer sufferers.”